Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 2/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PARG | Q86W56 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565211 | 1.00 | CA1 (0.52) | CA1CA2CA4CA6NSD2 | |
| SCHEMBL2803354 | 0.85 | NSD2 (0.58) | NSD2MAPTKDM4EMEN1NPC1 | |
| SCHEMBL7360565 | 0.85 | NSD2 (0.51) | CA1CA2CA4CA6NSD2 | |
| SCHEMBL20511875 | 0.83 | NSD2 (0.50) | CA1CA2CA4CA6NSD2 | |
| SCHEMBL15916151 | 0.82 | CA1 (0.46) | CA1CA2CA4CA6MAPT | |
| SCHEMBL29535297 | 0.82 | NSD2 (0.49) | CA1CA2CA4CA6NSD2 | |
| SCHEMBL3560744 | 0.82 | RECQL (0.53) | CA1CA2CA4CA6MAPT | |
| SCHEMBL15916160 | 0.80 | RECQL (0.48) | CA1CA2CA4CA6MAPT | |
| SCHEMBL14675988 | 0.80 | POLB (0.48) | CA1CA2CA4CA6MAPT | |
| SCHEMBL15916175 | 0.80 | RECQL (0.48) | CA1CA2CA4CA6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3070085-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-2951170-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| EP-2947085-B1 | OXAZOLIDONE COMPOUNDS, METHOD FOR PREPARING AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2017-09-13 | — | — | EP | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| EP-2451782-B1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-9382265-B2 | Oxazolidone compound, preparing method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-5312820-A | Angiotensin antagonist for treatment of hypertension | MERCK & CO., INC. (US) | 1994-05-17 | — | — | US | disclosed |
| US-5262412-A | Angiotensin II antagonists, hypotensive agents, treatment of congestive heart failure and glaucoma | MERCK & CO., INC. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5260285-A | Substituted imidazopyridazines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5250521-A | Administering in treatment of eleuated blood pressure, conjestive heart failure and ocular hypertension | MERCK & CO., INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0523141-A4 | SUBSTITUTED PYRAZOLES, ISOXAZOLES AND ISOTHIAZOLES | — | 1993-04-21 | — | — | EP | disclosed |
| EP-0526001-A1 | Substituted triazolinones | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1993001177-A1 | SUBSTITUTED TRIAZOLINONES | MERCK & CO., INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| EP-0523141-A1 | SUBSTITUTED PYRAZOLES, ISOXAZOLES AND ISOTHIAZOLES | MERCK & CO. INC. (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0490587-A1 | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| WO-1991015479-A1 | SUBSTITUTED PYRAZOLES, ISOXAZOLES AND ISOTHIAZOLES | MERCK & CO., INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | CA1 3447/4885CA2 4418/4885CA4 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.